2026年6月最新影响因子数据已更新，欢迎查询使用。如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
体验更多LetPub AI科研工具 >> | |
| 近期推荐： | 热 全流程投稿协助套餐服务 | 热 SCI论文AI润色+人工QC服务 | 新 聚合物期刊JPM征稿｜IF持续上升 + APC折扣 | 热 Springer Nature特刊征稿 |
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | Cancer Pathogenesis and Therapy （此期刊被最新的JCR期刊ESCI收录） LetPub评分 0.0
50人评分
我要评分
声誉 0.0 影响力 0.0 速度 0.0 | |||||||||||||||||||||||||||||
| 期刊ISSN | 2097-2563 | 安装APP，查看期刊最新消息
| ||||||||||||||||||||||||||||
| E-ISSN | 2949-7132 | |||||||||||||||||||||||||||||
| 2025-2026最新影响因子 （数据来源于搜索引擎） | 5.9 点击查看影响因子趋势图 | |||||||||||||||||||||||||||||
| 实时影响因子 | - | |||||||||||||||||||||||||||||
| 2025-2026自引率 | 8.5%点击查看自引率趋势图 | |||||||||||||||||||||||||||||
| 五年影响因子 | 5.9 | |||||||||||||||||||||||||||||
| JCI期刊引文指标 | 0.76 | |||||||||||||||||||||||||||||
| h-index | 暂无h-index数据 | |||||||||||||||||||||||||||||
| CiteScore （ 2026年6月最新版） |
| |||||||||||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||||||||||
| 期刊官方网站 | https://www.sciencedirect.com/journal/cancer-pathogenesis-and-therapy | |||||||||||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||||||||||
| 期刊投稿网址 | ||||||||||||||||||||||||||||||
| 该期刊中国学者近期发文 - New | Coronary artery calcification and carotid artery stenosis as late cardiovascular effects of radiotherapy for parotid gland malignancy: A case report and clinical considerations Author: Li, Yanwei; Fan, Zhimin; Liu, Meiyan Journal: CANCER PATHOGENESIS AND THERAPY. 2026; Vol. 4, Issue 4, pp. 331-334. DOI: 10.1016/j.cpt.2026.01.005 Metabolic pathways and chemotherapy resistance in acute myeloid leukemia (AML): Insights into Enoyl-CoA hydratase domain-containing protein 3 (ECHDC3) as a potential therapeutic target Author: Zhao, Yijing; Guo, Hanfei; Niu, Liting; Zhao, Jinfang Journal: CANCER PATHOGENESIS AND THERAPY. 2026; Vol. 4, Issue 4, pp. 310-320. DOI: 10.1016/j.cpt.2025.08.002 Role of Ferredoxin 1 (FDX1) in cancer and its therapeutic potential Author: He, Fen; Zhao, Hongyan; Gao, Ruixin; Lu, Maoyou; Wang, Siqi; Chen, Yu; Peng, Lijun; Xia, Jiliang Journal: CANCER PATHOGENESIS AND THERAPY. 2026; Vol. 4, Issue 4, pp. 249-260. DOI: 10.1016/j.cpt.2025.11.002 Low-dose decitabine increases peripheral NKT-like cell proportions in patients with chronic myeloid neoplasms Author: Zhang, Zhanqiang; Wang, Yue; Zhang, Haojun; Zhao, Jinjing; Yang, Zhili; Wang, Xiaoqian; Tang, Yujie; Lu, Xuechun; Xu, Rui Journal: CANCER PATHOGENESIS AND THERAPY. 2026; Vol. 4, Issue 4, pp. 321-325. DOI: 10.1016/j.cpt.2026.01.002 | |||||||||||||||||||||||||||||
| 期刊语言要求 | Language Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service. 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足Cancer Pathogenesis and Therapy的语言要求，还能让Cancer Pathogenesis and Therapy编辑和审稿人得到更好的审稿体验，让稿件最大限度地被Cancer Pathogenesis and Therapy编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||||||||||
| 是否OA开放访问 | Yes | |||||||||||||||||||||||||||||
OA期刊相关信息 | 文章处理费：需要（ USD1100; ） 文章处理费豁免：查看说明 其他费用：没有 期刊主题关键词：oncological pharmacology、cancer genomics、cancer informatics、oncology、cancer prevention、cancer research 相关链接：Aims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | |||||||||||||||||||||||||||||
| 通讯方式 | ||||||||||||||||||||||||||||||
| 出版商 | Elsevier | |||||||||||||||||||||||||||||
| 涉及的研究方向 | Medicine-Oncology | |||||||||||||||||||||||||||||
| 出版国家或地区 | Netherlands | |||||||||||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||||||||||
| 出版周期 | ||||||||||||||||||||||||||||||
| 出版年份 | 0 | |||||||||||||||||||||||||||||
| 年文章数 | 51点击查看年文章数趋势图 | |||||||||||||||||||||||||||||
| Gold OA文章占比 | 100.00% | |||||||||||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 54.90% | |||||||||||||||||||||||||||||
| WOS期刊JCR分区 （ 2025-2026年最新版） | WOS分区等级：1区
| |||||||||||||||||||||||||||||
| 期刊分区表预警名单 | 2026年03月发布的新锐学术版：不在预警名单中 2025年03月发布的2025版：不在预警名单中 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||||||||||
  | ||||||||||||||||||||||||||||||
| 《新锐期刊分区表》 （ 2026年3月发布） | 点击查看期刊分区表趋势图
| |||||||||||||||||||||||||||||
| 期刊分区表 （ 2025年3月升级版） |
| |||||||||||||||||||||||||||||
| 期刊分区表 （ 2023年12月旧的升级版） | （没有被旧的期刊分区表收录，仅供参考） | |||||||||||||||||||||||||||||
| SCI期刊收录coverage | Emerging Sources Citation Index (ESCI) Scopus (CiteScore) Directory of Open Access Journals (DOAJ) | |||||||||||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2097-2563%5BISSN%5D | |||||||||||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 8 Weeks | |||||||||||||||||||||||||||||
| 平均录用比例 | 网友分享经验： | |||||||||||||||||||||||||||||
| 版面费/APC文章处理费信息 | 文章处理费：需要（ USD1100; ） 文章处理费豁免：查看说明 其他费用：没有 LetPub提供文章处理费（APC）支持服务，可以用人民币支付版面费啦！ | |||||||||||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在Cancer Pathogenesis and Therapy顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Coronary artery calcification and carotid artery stenosis as late cardiovascular effects of radiotherapy for parotid gland malignancy: A case report and clinical considerations Author: Li, Yanwei; Fan, Zhimin; Liu, Meiyan Journal: CANCER PATHOGENESIS AND THERAPY. 2026; Vol. 4, Issue 4, pp. 331-334. DOI: 10.1016/j.cpt.2026.01.005 PubMed DOI |
| 2. | Metabolic pathways and chemotherapy resistance in acute myeloid leukemia (AML): Insights into Enoyl-CoA hydratase domain-containing protein 3 (ECHDC3) as a potential therapeutic target Author: Zhao, Yijing; Guo, Hanfei; Niu, Liting; Zhao, Jinfang Journal: CANCER PATHOGENESIS AND THERAPY. 2026; Vol. 4, Issue 4, pp. 310-320. DOI: 10.1016/j.cpt.2025.08.002 PubMed DOI |
| 3. | Role of Ferredoxin 1 (FDX1) in cancer and its therapeutic potential Author: He, Fen; Zhao, Hongyan; Gao, Ruixin; Lu, Maoyou; Wang, Siqi; Chen, Yu; Peng, Lijun; Xia, Jiliang Journal: CANCER PATHOGENESIS AND THERAPY. 2026; Vol. 4, Issue 4, pp. 249-260. DOI: 10.1016/j.cpt.2025.11.002 PubMed DOI |
| 4. | Low-dose decitabine increases peripheral NKT-like cell proportions in patients with chronic myeloid neoplasms Author: Zhang, Zhanqiang; Wang, Yue; Zhang, Haojun; Zhao, Jinjing; Yang, Zhili; Wang, Xiaoqian; Tang, Yujie; Lu, Xuechun; Xu, Rui Journal: CANCER PATHOGENESIS AND THERAPY. 2026; Vol. 4, Issue 4, pp. 321-325. DOI: 10.1016/j.cpt.2026.01.002 DOI |
| 5. | Safety and efficacy of JWATM204, a novel Glypican-3 (GPC3)-targeted CAR T cell therapy for advanced hepatocellular carcinoma: A phase I dose-escalation study Author: Yang, Yongqiang; Tang, Jing; Wu, Zilong; Zhang, Jinfeng; Liu, Dongen; Fan, Jun; Wu, Gang; Zhang, Tao; Xue, Jun Journal: CANCER PATHOGENESIS AND THERAPY. 2026; Vol. 4, Issue 4, pp. 297-309. DOI: 10.1016/j.cpt.2025.12.002 PubMed DOI |
| 6. | Low-dose ruxolitinib as first-line therapy for acute graft-versus-host disease (aGVHD) increases the risk of Epstein-Barr virus (EBV) reactivation but not posttransplant lymphoproliferative disease (PTLD) Author: Qian, Kun; Xing, Shuangyi; Wei, Yujun; Wang, Lili; Yang, Jingjing; Li, Fei; Gu, Zhenyang; Wang, Nan; Dou, Liping; Liu, Daihong Journal: CANCER PATHOGENESIS AND THERAPY. 2026; Vol. 4, Issue 3, pp. 230-240. DOI: 10.1016/j.cpt.2025.12.001 PubMed DOI |
| 7. | The global landscape of particle beam radiotherapy trials over the past 15 years Author: Chen, Wei; Wu, Chenfei; Xiao, Mingying; Chen, Runzhe; Guo, Lanlan; Hu, Haoyue; Li, Xuan; Dong, Baiqiang; Huang, Yuanyang; Chen, Ming Journal: CANCER PATHOGENESIS AND THERAPY. 2026; Vol. 4, Issue 3, pp. 219-229. DOI: 10.1016/j.cpt.2025.09.002 PubMed DOI |
| 8. | Efficacy of chemotherapy combined with immunotherapy in advanced lung adenocarcinoma harboring epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations: A retrospective comparative study Author: Zhao, Ying; Yao, Xiujing; Li, Ruyue; Dong, Xue; Li, Ying; Li, Yintao Journal: CANCER PATHOGENESIS AND THERAPY. 2026; Vol. 4, Issue 3, pp. 241-248. DOI: 10.1016/j.cpt.2025.09.001 PubMed DOI |
| 9. | Targeting immune checkpoint therapy: The role of manganese in tumor immunotherapy Author: Lyu, Xingyao; Li, Bixia; Lin, Zhijie Journal: CANCER PATHOGENESIS AND THERAPY. 2026; Vol. 4, Issue 3, pp. 165-173. DOI: 10.1016/j.cpt.2025.10.001 PubMed DOI |
| 10. | Authors' Reply: Survival Outcomes Associated with Surgery, Radiotherapy, and Chemotherapy in Metastatic Vulvar Cancer Author: Meng, Xiaolin; Guo, Shuaiqingying; Feng, Xue; Ai, Jihui; Yang, Jie Journal: CANCER PATHOGENESIS AND THERAPY. 2026; Vol. 4, Issue 2, pp. -. DOI: |
|
|
  | ||||||||||||||||
|
投稿状态统计： 我要评分： | ||||||||||||||||
| 投稿前担心稿件结构或语言不够规范？试试稿件自查工具，一键检测 >> | ||||||||||||||||
|
||||||||||||||||
同领域作者分享投稿经验：共0条 |
||||||||||||||||
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2026 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
投稿信 (Cover Letter) 模板
